Brain
Parkinson 1B BP45361
This research section investigates the safety and efficacy of RO7568282 in people with Parkinson's disease…
*Would you prefer to call? We will take the time to answer your questions.
Fixed conditions apply to this research. The following are stated in plain language.
If you are unsure whether you meet these requirements, you can always register. We will then look together to see if you are suitable to participate.
The aim of this study is to determine how safe and effective the new drug BIIB122 is for the treatment of participants with the early stage of Parkinson’s disease. We compare the efficacy of the new drug BIIB122 with that of a placebo (a drug without an active ingredient, a ‘dummy drug’). The investigational drug is administered orally.
This study examines whether the drug BIIB122 can help slow down the progression of the disease. Microglia cells are activated by inflammation; several studies have shown that overactivating these cells is harmful to the brain and may play a role in Parkinson’s disease. BIIB122 reduces the activation of microglia cells.
You will visit the research center approximately 9 to 20 times, over approximately 55 to 151 weeks. The duration of the study and the number of visits depend on when you start the study. The duration of each visit is not always the same because not all visits involve the same tests. Some of these visits are 6 hours long, others are 3.5 hours or shorter. The study takes place in Amsterdam and Zwolle; you choose the location that suits you best. If you wish, someone you know well or a family member can accompany you to the visits.
This research is being conducted on behalf of Biogen.
What does it bring me?
A two-minute form: name, phone number, email address, place of residence and diagnosis. No medical questions. You are only asking for information with this form.
Two minutes, at home. After registering, you will hear from us within a week.
This research is being conducted at two of our three locations. You choose the location that works best for you.
Yes, you can continue to use your current medications. After your registration, we will carefully review your current medication use. If you use many (heavy) medications, that may be a reason not to allow you to participate in a study, but this varies per study. In no case should you stop using your current medications.
The regular treatment by your current specialist will generally continue during the period of the investigation. Progress Clinical Research will inform your specialist and your GP about your participation. During the investigation, checks will be performed at several points. If there are any abnormalities in the results, Progress Clinical Research, with your consent, will contact your GP or treating specialist. Your GP or specialist is also welcome to consult with one of our research doctors regarding changes in your health.
Progress Clinical Research mainly conducts research on patients who have already been diagnosed, but we sometimes also conduct studies where healthy volunteers are sought. So you can also sign up if no diagnosis has been made.
Yes, stopping can be done at any time. There are no conditions attached to this.
Yes, you can read about the ongoing studies on our website. You can also indicate a preference for a particular study: for example, would you prefer to participate in a short study (for example, a few months) or a long study (for example, several years)? Progress Clinical Research determines, among other things, based on your medical history, age, and current medication use whether you are suitable for the study of your preference. Different criteria apply for each study, and the possibilities are discussed with the study doctor. Participation in a study is always done in consultation.
Steps to follow when participating in research:
Yes, that is possible. If you have completed the entire study, the results are reviewed: Have you remained stable, progressed, or actually regressed? Subsequently, we can decide together whether to continue with the study or conclude your period of employment at Progress Clinical Research.
All patients receive reimbursement for travel and parking costs automatically. Lunch is also provided for longer visits. There is no other financial reimbursement. You participate in a clinical drug trial because the medicines offer you the chance to improve and because you want to help future generations. Another benefit of participating in a research study is that your disease is monitored closely and you receive good guidance and support from professionals during the study.
In some clinical drug trials, some of the patients receive the active drug. The other part of the patients receives a placebo. A placebo is a drug without active substances. The patients are randomly placed in a group by a computer. Both the patients and the doctors do not know who is in which group. However, there are also drug trials where no placebo is used; all the patients receive the study drug.
A computer randomly places the patients in a group. One group receives the active drug, the other group receives a placebo. A placebo is a drug without active ingredients. No one involved in the research knows which group you belong to. This is called blinding.
The investigational medication often comes in the form of tablets. You can take them at home daily. Depending on the type of drug being studied, the medication may also be administered every few weeks via an injection or infusion. This is done at Progress Clinical Research under the supervision of a doctor.
In most drug trials, there is indeed a medicinal product that is active and a medicinal product that is not active (placebo). Progress Clinical Research has no control over the allocation of the funds: this happens automatically and Progress Clinical Research does not receive that information either. Only in acute emergencies can Progress Clinical Research request this information. There are also a number of drug trials that use only active substances. During an initial consultation, the research doctor can inform you about this.
No, the treatments at Progress Clinical Research are not covered by health insurance. Therefore, you do not have to worry about any out-of-pocket costs. For each drug trial, an individual insurance policy is taken out for all participants. If you have any questions about this, please ask during the initial consultation or during the initial meeting. Please note that other matters, such as follow-up visits with your own specialist (outside of Progress Clinical Research), are still covered by your own health insurance.
Is this research not relevant? These studies within the same disease area are now also looking for participants.
Brain
This research section investigates the safety and efficacy of RO7568282 in people with Parkinson's disease…
*Would you prefer to call? We will take the time to answer your questions.
Brain
In this study, we examine whether KarXT, together with KarX-EC, can help people with...
*Would you prefer to call? We will take the time to answer your questions.
Brain
For people with MCI or mild Alzheimer's, a BMI of 18–40 and an MMSE score of 12–22.…
*Would you prefer to call? We will take the time to answer your questions.